cognitive symptoms phenotype
Evidence from:
primary |
all sources
Related entities (5)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| cannabinoids | associated_with | cognitive symptoms | — | 1 |
| cannabinoids | risk_factor_for | cognitive symptoms | — | 1 |
| cognitive symptoms | associated_with | schizophrenia | — | 1 |
| positive symptoms | associated_with | cognitive symptoms | — | 1 |
| sarcosine | protective_against | cognitive symptoms | — | 1 |
Mentioned in (7)
Papers in which this entity is mentioned.
- Associations Between Cannabis Use, Polygenic Liability for Schizophrenia, and Cannabis-related Experiences in a Sample of Cannabis Users. (2023)
- Cerebral organoids reveal early cortical maldevelopment in schizophrenia-computational anatomy and genomics, role of FGFR1. (2017)
- Social cognition as an RDoC domain. (2016)
- Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study. (2015)
- The impact of environmental factors in severe psychiatric disorders. (2014)
- Rethinking schizophrenia in the context of normal neurodevelopment. (2013)
- Cannabis and psychosis/schizophrenia: human studies. (2009)
Merged raw entities (2)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| cognitive symptoms | phenotype | 5 | 9 |
| disorganized speech | phenotype | 2 | 2 |